Cemiplimab

Research use only, not for human use.

Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1/PD-L1 pathway, serving as a checkpoint inhibitor.

Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.

——

Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model.Animal Model:Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells Dosage:10 mg/kg Administration:Intraperitoneal injection; five injections within 2 weeks Result:Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.

——

Others

Other Targets

Others

——

——

1801342-60-8

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years